CoChat

Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world

Open access

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 13 of the 34 sources its claims cite were checked for support.

Abstract

Both apixaban and rivaroxaban have been approved for use in acute venous thromboembolism (VTE). Although indirect comparison through network meta-analyses of randomized trials have been performed to compare the efficacy and safety of these agents, further comparison between these agents was lacking until recently. We sought to systematically review and carry out a meta-analysis of studies to further compare apixaban with rivaroxaban from multiple studies done in the real-world settings. Studies comparing rivaroxaban with apixaban in patients with acute VTE were identified through electronic literature searches of MEDLINE, EMBASE, Scopus, and the Cochrane library up to May 2019. Study-specific risk ratios (RRs) were calculated and combined using a random-effects model meta-analysis. In an analysis involving 24 041 patients, recurrent VTE within 6 months occurred in 56 of 4897 patients (1.14%) in the apixaban group and 258 of 19 144 patients (1.35%) in the rivaroxaban group (RR, 0.89; 95% confidence interval [CI], 0.67-1.19; P = .45). Clinically relevant major bleeding occurred in 85 of 11 559 patients (0.74%) in the apixaban group and 350 of 33 909 patients (1.03%) in the rivaroxaban group (RR, 0.73; 95% CI, 0.58-0.93; P = .01). Clinically relevant nonmajor bleeding occurred in 169 of 3417 patients (4.95%) in the apixaban group and 1094 of 12 475 patients (8.77%) in the rivaroxaban group (RR, 0.59; 95% CI, 0.50-0.70; P < .01). Apixaban shows equivalent efficacy in prevention of recurrent VTE but decreased risk of major and minor bleeding events compared with rivaroxaban.

Overview

CoChat Summary

TL;DR

This real-world systematic review and meta-analysis found that apixaban and rivaroxaban had similar efficacy for preventing recurrent VTE in acute VTE, but apixaban had lower bleeding risk. Across 5 studies and 45,468 patients, major and minor bleeding were significantly less frequent with apixaban.

Key findings

  • The review included 5 studies with a total of 45,468 patients analyzed for recurrent VTE and bleeding outcomes.
  • For recurrent VTE up to 6 months, there was no significant difference between apixaban and rivaroxaban: 1.14% vs 1.35%; RR 0.89 (95% CI 0.67-1.19; P = .45).
  • Clinically relevant major bleeding was lower with apixaban: 0.74% vs 1.03%; RR 0.73 (95% CI 0.58-0.93; P = .01).
  • Clinically relevant nonmajor bleeding was also lower with apixaban: 4.95% vs 8.77%; RR 0.59 (95% CI 0.50-0.70; P < .01). The paper also reports a composite of major and minor bleeding of 5.56% vs 9.51%; RR 0.60 (95% CI 0.52-0.70).

Methods

  • PRISMA-guided systematic review of studies published from database inception to May 2019, searching MEDLINE, Cochrane Library, EMBASE, and conference abstracts; no language restriction.
  • Included human studies with acute VTE that directly compared apixaban vs rivaroxaban and reported VTE or bleeding outcomes up to 3 months minimum; studies with AF-only populations or indirect comparisons to warfarin/LMWH were excluded.
  • Outcomes were pooled using a random-effects meta-analysis in RevMan 5.3, reporting risk ratios (RRs) and 95% CIs; heterogeneity was assessed with I².

Limitations

  • The paper states that the included studies were nonrandomized, so unaccountable confounders may remain despite attempts to reduce confounding.
  • It also states that doses and compliance could not be determined from the database/registry studies, and that intracranial bleeding, gastrointestinal bleeding, cardiac bleeding, and mortality were inconsistently reported.
  • Evident from the text: the evidence base was small (5 studies) and follow-up was limited to about 6 months, so longer-term comparative effects are not established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2019000572

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

10 Valid · 2 Not valid · 10 Not checked · 31 Own results and interpretations

25 more claims

Create a free account to see all 53 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 16
  • It may state two separate claims as one. 11

Create a free account to see these claims.

Citations

Cites

Show all 20 references

Cited by

See all 62

Metadata

Authors
Aryal, M. R., Gosain, R., Donato, A., Yu, H., Katel, A., Bhandari, Y., Dhital, R., & Kouides, P. A.
Affiliations
  • Roswell Park Comprehensive Cancer Center (US)
  • Reading Hospital (US)
  • Kathmandu University (NP)
  • University at Buffalo, State University of New York (US)
  • Unity Health System (US)
Corresponding author
  • Aryal, Madan Raj
  • Gosain, Rohit
Venue
Blood Advances
Published
2019-08-12
Volume
3
Issue
15
Pages
2381-2387
ISSN
  • 2473-9529 (ISSN-L)
  • 2473-9537
OpenAlex
W2968913818
Cited by
62
References
19
Citations by year
2026: 11 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 16 · 2021: 7 · 2020: 11 · 2019: 1
FWCI
2.49
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Blood Advances (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords
apixaban, rivaroxaban, venous thromboembolism, recurrent venous thromboembolism, major bleeding, direct oral anticoagulants, real-world evidence, anticoagulant efficacy and safety
MeSH terms
Rivaroxaban, Blood Coagulation, Hemorrhage, Humans, Pyrazoles, Pyridones, Odds Ratio, Treatment Outcome, Venous Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. https://app.cochat.ai/papers/10.1182/bloodadvances.2019000572
The paper
Aryal, M. R., Gosain, R., Donato, A., Yu, H., Katel, A., Bhandari, Y., Dhital, R., & Kouides, P. A. (2019). Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Advances. https://doi.org/10.1182/bloodadvances.2019000572

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.